Outlook Therapeutics (OTLK) 10-Q 14 Feb 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2023	Feb. 12, 2024
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-37759
Entity Registrant Name	OUTLOOK THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3982704
Entity Address, Address Line One	485 Route 1 South
Entity Address, Address Line Two	Building F, Suite 320
Entity Address, City or Town	Iselin
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08830
City Area Code	609
Local Phone Number	619-3990
Title of 12(b) Security	Common Stock
Trading Symbol	OTLK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		260,257,517
Entity Central Index Key	0001649989
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 10,356,630	$ 23,391,982
Prepaid expenses and other current assets	10,032,579	7,587,216
Total current assets	20,389,209	30,979,198
Operating lease right-of-use assets, net	14,956	26,172
Equity method investment	796,480	793,932
Other assets	484,320	501,299
Total assets	21,684,965	32,300,601
Current liabilities:
Current portion of long-term debt	36,544,000	35,551,000
Current portion of finance lease liabilities	1,084	4,267
Accounts payable	3,480,326	6,574,523
Accrued expenses	4,086,770	2,745,740
Income taxes payable	1,856,629	1,856,629
Total current liabilities	45,968,809	46,732,159
Warrant liability	59,561	6,219
Total liabilities	46,028,370	46,738,378
Commitments and contingencies (Note 8)
Convertible preferred stock:
Total convertible preferred stock
Stockholders' deficit:
Preferred stock, value
Common stock, par value $0.01 per share; 425,000,000 shares authorized; 260,257,517 shares issued and outstanding at December 31, 2023 and September 30, 2023	2,602,574	2,602,574
Additional paid-in capital	452,150,446	450,877,835
Accumulated deficit	(479,096,425)	(467,918,186)
Total stockholders' deficit	(24,343,405)	(14,437,777)
Total liabilities, convertible preferred stock and stockholders' deficit	21,684,965	32,300,601
Series A convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series A-1 convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series B convertible preferred stock
Stockholders' deficit:
Preferred stock, value

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (unaudited) (Parentheticals) - $ / shares	Dec. 31, 2023	Sep. 30, 2023
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	7,300,000	7,300,000
Preferred stock, shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	425,000,000	425,000,000
Common stock, shares issued	260,257,517	260,257,517
Common stock, shares outstanding	260,257,517	260,257,517
Series A convertible preferred stock
Convertible stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock outstanding	0	0
Series A-1 convertible preferred stock
Convertible stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	200,000	200,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock outstanding	0	0
Series B convertible preferred stock
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 4,529,358	$ 9,862,424
General and administrative	5,793,764	5,825,604
Loss from operations	(10,323,122)	(15,688,028)
Income on equity method investment	(2,548)	(21,505)
Interest expense, net	(188,677)	2,448,591
Loss on extinguishment of debt		577,659
Change in fair value of promissory notes	993,000
Change in fair value of warrant liability	53,342	(30,260)
Net loss	$ (11,178,239)	$ (18,662,513)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (0.04)	$ (0.08)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.04)	$ (0.08)
Weighted average shares outstanding, basic (in shares)	260,257,517	227,410,533
Weighted average shares outstanding, diluted (in shares)	260,257,517	227,410,533

Consolidated Statements of Stoc

Consolidated Statements of Stockholders (Deficit) Equity (unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2022	$ 2,273,105	$ 415,398,984	$ (408,935,518)	$ 8,736,571
Balance, beginning (in shares) at Sep. 30, 2022	227,310,572
Increase (Decrease) in Stockholders' Equity
Sale of common stock, net of issuance costs	$ 293,562	23,998,598		24,292,160
Sale of common stock, net of issuance costs (in shares)	29,356,222
Stock-based compensation expense		1,392,393		1,392,393
Net loss			(18,662,513)	(18,662,513)
Balance at Dec. 31, 2022	$ 2,566,667	440,789,975	(427,598,031)	15,758,611
Balance, ending (in shares) at Dec. 31, 2022	256,666,794
Balance at Sep. 30, 2023	$ 2,602,574	450,877,835	(467,918,186)	(14,437,777)
Balance, beginning (in shares) at Sep. 30, 2023	260,257,517
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense		1,272,611		1,272,611
Net loss			(11,178,239)	(11,178,239)
Balance at Dec. 31, 2023	$ 2,602,574	$ 452,150,446	$ (479,096,425)	$ (24,343,405)
Balance, ending (in shares) at Dec. 31, 2023	260,257,517

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
OPERATING ACTIVITIES
Net loss	$ (11,178,239)	$ (18,662,513)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28,195	10,778
Loss on extinguishment of debt		577,659
Non-cash interest expense		2,529,830
Stock-based compensation	1,272,611	1,392,393
Change in fair value of promissory notes	993,000
Change in fair value of warrant liability	53,342	(30,260)
Income on equity method investment	(2,548)	(21,505)
Interest paid on debt		(1,158,609)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,445,363)	788,509
Operating lease liabilities		(11,422)
Accounts payable	(3,094,197)	678,394
Accrued expenses	1,341,030	5,005,500
Net cash used in operating activities	(13,032,169)	(8,901,246)
FINANCING ACTIVITIES
Proceeds from the sale of common stock, net of issuance costs		24,637,009
Proceeds from debt		30,000,000
Payments of finance lease obligations	(3,183)	(2,797)
Repayment of debt		(10,220,000)
Payment of financing costs		(568,930)
Net cash (used in) provided by financing activities	(3,183)	43,845,282
Net (decrease) increase in cash and cash equivalents	(13,035,352)	34,944,036
Cash and cash equivalents at beginning of period	23,391,982	17,396,812
Cash and cash equivalents at end of period	$ 10,356,630	52,340,848
Supplemental disclosure of cash flow information:
Cash paid for interest		1,159,008
Supplemental schedule of non-cash financing activities:
Debt issuance costs in accrued expenses		254,964
Common stock issuance costs in accrued expenses		339,275
Deferred offering costs amortization		$ 5,573

Organization and Description of

Organization and Description of Business	3 Months Ended
	Dec. 31, 2023
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the U.S. Food and Drug Administration (“FDA”) in support of the Company’s Biologics License Application (“BLA”) for ONS-5010. In December 2023, the Company submitted a Special Protocol Assessment (“SPA”) to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA’s requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010 BLA. In January 2024, the Company received confirmation that the FDA has reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA’s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter (“CRL”). The first subject was enrolled in NORSE EIGHT in January 2024. In addition, through a Type A meeting and additional interactions, the Company has identified the approaches needed to resolve the chemistry, manufacturing and controls (“CMC”) comments in the CRL. Separately, in October 2022 the Company submitted a Marketing Authorization Application (“MAA”), for ONS-5010 with the European Medicines Agency (“EMA”). On December 22, 2022, the Company’s MAA was validated for review by the EMA. The formal review process of the MAA by the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) is now underway with an estimated decision date expected in the first half of calendar 2024. ONS-5010 is the Company’s sole product candidate in active development.

Liquidity

Liquidity	3 Months Ended
	Dec. 31, 2023
Liquidity
Liquidity	2. Liquidity The Company has incurred recurring losses and negative cash flows from operations since its inception and has an accumulated deficit of $479,096,425 as of December 31, 2023. As of December 31, 2023, the Company had $37,666,716 of principal, accrued interest and exit fees due under an unsecured convertible promissory note issued in December 2022 (the “December 2022 Note”), maturing on April 1, 2024. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited interim consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. In January 2024, the Company entered into a securities purchase agreement with the investors named therein, pursuant to which the Company agreed to sell and the investors agreed to purchase shares of common stock and accompanying warrants to purchase shares of common stock in a private placement (the "Private Placement”), for gross proceeds of up to $60,000,000 at closing, plus up to an additional $99,000,000 upon full cash exercise of the warrants. In addition, in January 2024, the Company entered into a securities purchase agreement with Syntone Ventures, LLC (“Syntone”), pursuant to which the Company agreed to sell and Syntone agreed to purchase shares of common stock and accompanying warrants to purchase shares of common stock in a private placement (the “Syntone Private Placement” and together with the Private Placement, the “Private Placements”), for gross proceeds of up to $5,000,000 at closing. Concurrently with the Private Placements, the Company entered into an amendment to the December 2022 Note (the “Note Amendment”), which, among other things, would extend the maturity of the December 2022 Note to July 1, 2025. Both the Private Placements and the Note Amendment are subject to satisfaction of certain closing conditions, including various required stockholder approvals and, with respect to the Syntone Private Placement, certain regulatory approvals. The Private Placements will not close, the shares of common stock and warrants will not be issued and the proceeds of the Private Placements will not be received by the Company unless and until the closing conditions are satisfied. Similarly, the Note Amendment will not be effective unless the relevant conditions are satisfied. Therefore, there can be no assurance that the Private Placements and the Note Amendment will be successful. See Note 12 for additional information on the Private Placements and the Note Amendment. Management does not believe that the existing cash and cash equivalents as of December 31, 2023 are sufficient to fund the Company’s operations through one year from the Form 10-Q filing date. However, management does believe that the existing cash and cash equivalents when combined with the expected proceeds from the Private Placements (subject to closing conditions being met and meeting the requirements for calling the associated warrants) are sufficient to support the Company’s operations through June 2025. If stockholders do not approve the Private Placements or the change in terms for the December 2022 Note at the upcoming annual meeting of stockholders, it would raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might be necessary if it is unable to continue as a going concern. The Company’s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company’s ability to successfully begin marketing of its product candidates or complete revenue-generating partnerships with other companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company’s proposed future products.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	3. Basis of Presentation and Summary of Significant Accounting Policies Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of December 31, 2023 and its results of operations for the three months ended December 31, 2023 and 2022, cash flows for the three months ended December 31, 2023 and 2022, and stockholders’ (deficit) equity for the three months ended December 31, 2023 and 2022. Operating results for the three months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending September 30, 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended September 30, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on December 22, 2023. Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, such as the current macroeconomic environment, including as a result of inflation, high interest rates or ongoing overseas conflict, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Net loss per share Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Potentially dilutive securities include warrants, performance-based stock options and units, stock options and non-vested restricted stock unit (“RSU”) awards using the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company’s loss. The following table sets forth the computation of basic loss per share and diluted loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Net loss attributable to common stockholders ​ $ (11,178,239) ​ $ (18,662,513) Common stock shares outstanding (weighted average) ​ ​ 260,257,517 ​ ​ 227,410,533 Basic and diluted net loss per share ​ $ (0.04) ​ $ (0.08) ​ The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding as of December 31, 2023 and 2022, as they would be antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ 2023 2022 ​ Performance-based stock units ​ 2,470 ​ 2,470 ​ Performance-based stock options ​ 700,000 ​ 1,900,000 ​ Stock options ​ 25,982,109 ​ 20,726,330 ​ Common stock warrants ​ 7,328,549 ​ 7,328,549 ​ Convertible debt ​ 17,519,402 ​ 15,910,000 (i) ​ (i) The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of $2.00 per share, which is subject to change as described in Note 7. ​ Recently issued accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 31, 2023
Fair Value Measurements
Fair Value Measurements	4. Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 - Quoted prices in active markets for identical assets or liabilities. ● Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following table presents the Company’s liabilities that are measured at fair value on a recurring basis: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured convertible promissory note ​ $ — ​ $ — ​ $ 36,544,000 Warrant liability ​ ​ — ​ ​ — ​ ​ 59,561 Total ​ $ — ​ $ — ​ $ 36,603,561 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured convertible promissory note ​ $ — ​ $ — ​ $ 35,551,000 Warrant liability ​ ​ — ​ ​ — ​ ​ 6,219 Total ​ $ — ​ $ — ​ $ 35,557,219 ​ The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for the warrant liability and unsecured convertible promissory note for the three months ended December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured Convertible ​ ​ ​ ​ Promissory Note Warrants Balance at October 1, 2023 ​ $ 35,551,000 ​ $ 6,219 Change in fair value ​ ​ 993,000 ​ ​ 53,342 Balance at December 31, 2023 ​ $ 36,544,000 ​ $ 59,561 ​ As further described in Note 7, the Company elected the fair value option to account for the December 2022 Note. The fair value of the December 2022 Note is estimated using a binomial lattice model, which evaluates the payouts under hold, convert or call decisions. Significant estimates in the binomial lattice model include the Company’s stock price, volatility, risk-free rate of return, and credit-adjusted discount rate. ​ The fair value of the December 2022 Note as of December 31, 2023 was estimated using a binomial lattice model with the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 ​ Term (years) ​ ​ 0.3 ​ ​ 0.3 ​ Stock price ​ $ 0.39 ​ $ 0.22 ​ Volatility ​ ​ 186.0 % ​ 71.0 % Risk-free rate ​ ​ 5.4 % ​ 5.5 % Dividend yield ​ ​ — % ​ — % Credit-adjusted discount rate ​ ​ 21.8 % ​ 22.8 % ​ The warrants issued in connection with the convertible senior secured notes originally issued pursuant to that certain Note and Warrant Purchase Agreement dated December 22, 2017 are classified as liabilities on the accompanying unaudited interim consolidated balance sheets as the warrants include cash settlement features at the option of the holders under certain circumstances. The warrant liability is revalued each reporting period with the change in fair value recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair value of the warrant liability is estimated using the Black-Scholes option pricing model using the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 ​ Risk-free interest rate ​ ​ 4.72 % ​ 5.30 % Remaining contractual term of warrants (years) ​ ​ 1.1 ​ ​ 1.4 ​ Expected volatility ​ ​ 235.4 % ​ 158.3 % Annual dividend yield ​ ​ — % ​ — % Fair value of common stock (per share) ​ $ 0.39 ​ $ 0.22 ​ ​

Equity Method Investment

Equity Method Investment	3 Months Ended
	Dec. 31, 2023
Equity Method Investment
Equity Method Investment	5. Equity Method Investment ​ In connection with the execution of a stock purchase agreement with Syntone Ventures LLC, the United States-based affiliate of Syntone Technologies Group Co. Ltd. (“Syntone PRC”) on May 22, 2020, the Company and Syntone PRC entered into a joint venture agreement pursuant to which they agreed to form a People’s Republic of China (“PRC”) joint venture, Beijing Syntone Biopharma Ltd (“Syntone JV”), that is 80% owned by Syntone PRC and 20% owned by the Company. As the Company can exert significant influence over, but does not control, Syntone JV’s operations through voting rights or representation on Syntone JV’s board of directors, the Company accounts for this investment using the equity method of accounting. Upon formation of Syntone JV in April 2021, the Company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010 in the greater China market, which includes Hong Kong, Taiwan and Macau. The Company made the initial investment of $900,000 in June 2020 and is committed to making capital contributions to Syntone JV of approximately $2,100,000, based upon the development plan contemplated in the license agreement. The maximum exposure to a loss as a result of the Company’s involvement in Syntone JV is limited to the initial investment and the future capital contributions totaling approximately $2,100,000.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Dec. 31, 2023
Accrued Expenses
Accrued Expenses	6. Accrued Expenses Accrued expenses consists of: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 Compensation ​ $ 1,112,512 ​ $ 919,970 Research and development ​ ​ 1,631,674 ​ ​ 1,234,192 Professional fees ​ ​ 1,161,512 ​ ​ 165,192 Other accrued expenses ​ ​ 181,072 ​ ​ 426,386 ​ ​ $ 4,086,770 ​ $ 2,745,740 ​

Debt

Debt	3 Months Ended
	Dec. 31, 2023
Debt
Debt	7. Debt ​ Debt consists of: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 September 30, 2023 Unsecured convertible promissory note (measured at fair value) ​ $ 36,544,000 ​ $ 35,551,000 Less: current portion ​ ​ (36,544,000) ​ ​ (35,551,000) Long-term debt ​ $ — ​ $ — ​ December 2022 Note On December 22, 2022, the Company entered into a Securities Purchase Agreement and issued the December 2022 Note with a face amount of $31,820,000 to Streeterville Capital, LLC (the “Lender”), the holder of the Company’s unsecured promissory note issued in November 2021 (the “November 2021 Note”). The December 2022 Note has an original issue discount of $1,820,000. The Company received net proceeds of $18,052,461 upon the closing on December 28, 2022 after deducting the Lender’s transaction costs in connection with the issuance and a full payment of the remaining outstanding principal and accrued interest on the November 2021 Note. The November 2021 Note was cancelled upon repayment. See below for additional disclosures relating to November 2021 Note. The December 2022 Note bears interest at 9.5% per annum and matures on April 1, 2024. The December 2022 Note contains customary covenants, including a restriction on the Company’s ability to pledge certain of the Company’s assets, subject to certain exceptions, without the Lender’s consent. Beginning on April 1, 2023, the Lender will have the right to convert the December 2022 Note at the Conversion Price (as defined below). The principal amount and conversion price of the December 2022 Note are subject to adjustment upon certain triggering events. In addition, the Company has the right to convert all or any portion of the outstanding balance under the December 2022 Note into shares of common stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the six-month anniversary of the closing date, the daily volume-weighted average price of the common stock on Nasdaq equals or exceeds $2.50 per share (subject to adjustments for stock splits and stock combinations) for a period of 30 consecutive trading days. Payments may be made by the Company (i) in cash, (ii) in shares of common stock, with the number of shares being equal to the portion of the applicable payment amount divided by the Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. Any payments made by the Company in cash, including prepayments or repayment at maturity, will be subject to an additional fee of 7.5%. Upon the occurrence of certain events described in the December 2022 Note, including, among others, the Company’s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender’s consent (each such event, a “Trigger Event”), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by 10% for a Major Trigger Event (as defined in the December 2022 Note) and 5% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within ten may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid. Under the December 2022 Note, “Conversion Price” means, prior to a Major Trigger Event, $2.00 per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $2.00 per share (subject to adjustment for stock splits and stock combinations), and (ii) 90% multiplied by the lowest closing bid price of the Company’s common stock in the three trading days prior to the date on which the conversion notice is delivered. If the Conversion Price is below $0.1756 per share, the Company will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a 10% participation right in any future debt or equity financings. In December 2023, the Company extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. The Company incurred a $475,000 extension fee, which was expensed in the three months ended December 31, 2023 and included in general and administrative expense in the unaudited interim consolidated statement of operations. In January 2024, the Company entered into the Note Amendment, which would further extend the maturity of the December 2022 Note to July 1, 2025. The Note Amendment is subject to satisfaction of certain closing conditions, including various required stockholder approvals. The Note Amendment will not be effective unless the relevant conditions are satisfied. Therefore, there can be no assurance that the Note Amendment will be successful. See Note 12 for additional information on the Note Amendment. The Company elected to account for the December 2022 Note at fair value (Note 4) and was not required to bifurcate the conversion option as a derivative and as a result the original issue discount of $1,820,000 and debt issuance costs were written off upon election to fair value and accounted for as interest. During the three months ended December 31, 2022 the Company recognized $2,074,964 of interest expense related to the December 2022 Note related to original issue discount of $1,820,000 and other third party debt issuance costs of $254,964 as the Company elected the fair value option. ​ November 2021 Note On November 16, 2021, the Company received $10,000,000 in net proceeds from the issuance of the November 2021 Note with a face amount of $10,220,000. Debt issuance costs totaling $820,000 were recorded as debt discount and were deducted from the principal. The debt discount was amortized as a component of interest expense over the term of the underlying debt using the effective interest method. The November 2021 Note bore interest at a rate of 9.5% per annum compounding daily and was set to mature on January 1, 2023. The Company could prepay all or a portion of the November 2021 Note at any time by paying 105% of the outstanding balance elected for pre-payment. ​ As discussed above, the November 2021 Note was cancelled using proceeds from the December 2022 Note issued to the same lender. The total repayment was $11,947,539, which represented 105% of the outstanding balance and included $1,158,609 of interest expense. The transaction has been accounted for as an extinguishment of the November 2021 Note. As a result, the Company recorded a loss on debt extinguishment of $577,659, which included $8,729 of unamortized debt discount, and prepayment fees of $568,930. ​ During the three months ended December 31, 2022, the Company recognized $454,866 of interest expense related to the November 2021 Note of which $190,775 was related to the amortization of debt discount.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2023
Commitments and Contingencies
Commitments and Contingencies	8. Commitments and Contingencies ​ Litigation On November 3, 2023, a securities class action lawsuit was filed against the Company and certain of its officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with allegedly false and misleading statements made by the Company related to the Company’s BLA during the period from December 29, 2022 through August 29, 2023. The complaint alleges, among other things, that the Company violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010 as a treatment for wet AMD and that we and/or our manufacturing partner had deficient CMC controls for ONS-5010, which remained unresolved at the time the Company’s BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve the Company’s BLA, and that the Company’s stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys’ fees. The pending lawsuit and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuit and any other related lawsuits is necessarily uncertain. The Company could be forced to expend significant resources in the defense of the pending lawsuit and any additional lawsuits, and the Company may not prevail. In addition, the Company may incur substantial legal fees and costs in connection with such lawsuits. The Company currently is not able to estimate the possible cost to it from these matters, as the pending lawsuit is currently at an early stage, and the Company cannot be certain how long it may take to resolve the pending lawsuit or the possible amount of any damages that the Company may be required to pay. Such amounts could be material to the Company’s financial statements if it does not prevail in the defense of the pending lawsuit and any other related lawsuits, or even if it does prevail. The Company has not established any reserve for any potential liability relating to the pending lawsuit and any other related lawsuits. It is possible that the Company could, in the future, incur judgments or enter into settlements of claims for monetary damages. Leases ​ Corporate office ​ In March 2021, the Company entered into a three-year term corporate office lease in Iselin, New Jersey that commenced on April 23, 2021. Equipment leases ​ The Company has equipment leases, with terms between 12 and 36 months, recorded as finance leases. The equipment leases bear interest between 4.0% and 13.0% per annum. ​ Certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include minimum payments that the Company is obligated to make under the non-cancelable initial terms of the leases as the renewal terms are at the Company’s option. Lease expense is recorded as research and development or general and administrative based on the use of the leased asset. ​ The components of lease cost for the three months ended December 31, 2023 and 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Lease cost: ​ ​ Amortization of right-of-use assets ​ $ — ​ $ — Interest on lease liabilities ​ 104 ​ 491 Total finance lease cost ​ 104 ​ 491 Operating lease cost ​ 11,217 ​ 11,217 Total lease cost ​ $ 11,321 ​ $ 11,708 ​ Amounts reported in the unaudited interim consolidated balance sheets for leases where the Company is the lessee are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 September 30, 2023 Operating leases: ​ ​ ​ Right-of-use asset ​ $ 14,956 ​ $ 26,172 Operating lease liabilities ​ — ​ — Finance leases: ​ ​ Right-of-use asset ​ $ — ​ $ — Financing lease liabilities ​ 1,084 ​ 4,267 Weighted-average remaining lease term (years): ​ ​ Operating leases ​ ​ 0.3 ​ ​ 0.6 Finance leases ​ — ​ 0.3 Weighted-average discount rate: ​ ​ Operating leases ​ ​ 7.5% ​ ​ 7.5% Finance leases ​ 13.0% ​ 13.0% ​ Other information related to leases for the three months ended December 31, 2023 and 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Cash paid for amounts included in the measurement of lease obligations: ​ ​ ​ Operating cash flows from finance leases ​ $ 104 ​ $ 491 Operating cash flows from operating leases ​ — ​ 11,861 Financing cash flows from finance leases ​ 3,183 ​ 2,797 ​ Future minimum lease payments under non-cancelable leases as of December 31, 2023 are as follows for the years ending September 30: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance leases 2024 (remaining one month) ​ ​ ​ ​ $ 1,096 Less: Imputed interest ​ ​ ​ ​ 12 Total lease obligations ​ ​ ​ ​ $ 1,084 ​

Common Stock and Stockholders'

Common Stock and Stockholders' Equity	3 Months Ended
	Dec. 31, 2023
Common Stock and Stockholders' Equity
Common Stock and Stockholders' Equity	9. Common Stock and Stockholders’ Equity Common stock On March 29, 2023, following receipt of stockholder approval at the Company’s 2023 annual meeting of stockholders, the number of authorized shares of common stock under the Company’s Certificate of Incorporation was increased from 325,000,000 shares to 425,000,000 shares. In December 2022, in a registered direct equity offering to certain institutional and accredited investors, including GMS Ventures and Investments (“GMS Ventures”), the Company’s largest stockholder, the Company issued 28,460,831 shares of common stock at a purchase price per share of $0.8784 for $23,208,679 in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of 14,230,418 shares of common stock in the registered direct equity offering. In connection with the registered direct equity offering, the Company issued to M.S. Howells & Co., the placement agent, warrants to purchase up to an aggregate of 515,755 shares of common stock at an exercise price of $1.05 per share, which warrants have a three-year term. H.C. Wainwright & Co. At-the-Market Offering Agreement On March 26, 2021, the Company entered into an At-the-Market Offering Agreement with H.C. Wainwright & Co., as sales agent (“Wainwright”) (the “Wainwright ATM Agreement” or the “Wainwright ATM Offering”), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $40,000,000 from time to time through Wainwright. The Company incurred financing costs of $197,654, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the Wainwright ATM Offering. Under the Wainwright ATM Agreement, the Company paid Wainwright a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the Wainwright ATM Agreement. The Company terminated the Wainwright ATM Agreement effective May 15, 2023. As a result, the Company wrote off unamortized deferred costs under the Wainwright ATM Agreement effective as of the termination date. During the three months ended December 31, 2022, the Company sold 895,391 shares of common stock under the Wainwright ATM Offering and generated $1,089,105 in net proceeds. The Company paid fees to Wainwright and other issuance costs of $38,799. BTIG, LLC At-the-Market Offering Agreement On May 16, 2023, the Company entered into an At-the-Market Sales Agreement with BTIG, LLC (“BTIG”) as sales agent (the “BTIG ATM Agreement” or the “BTIG ATM Offering”), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000,000 from time to time through BTIG. The Company incurred financing costs of $353,688, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the BTIG ATM Offering. As of December 31, 2023, $331,512 of such deferred costs are included in other assets on the unaudited interim consolidated balance sheets. Under the BTIG ATM Agreement, the Company pays BTIG a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms. No shares of common stock were sold under the BTIG ATM Offering during the three months ended December 31, 2023. Common stock warrants As of December 31, 2023, shares of common stock issuable upon the exercise of outstanding warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares of ​ ​ ​ ​ ​ common stock ​ ​ ​ ​ ​ issuable upon ​ ​ ​ ​ ​ exercise of ​ Exercise Price ​ Expiration Date warrants Per Share ​ December 22, 2024 (i) 277,128 ​ $ 12.00 ​ February 26, 2024 ​ 1,747,047 ​ $ 0.9535 ​ February 24, 2025 ​ 172,864 ​ $ 1.27 ​ April 13, 2025 (i) 145,686 ​ $ 12.00 ​ May 31, 2025 (i) 62,437 ​ $ 12.00 ​ June 22, 2025 ​ 191,268 ​ $ 1.51875 ​ December 28, 2025 ​ 515,755 ​ $ 1.0500 ​ January 28, 2026 ​ 2,116,364 ​ $ 1.25 ​ November 23, 2026 ​ 2,100,000 ​ $ 1.5625 ​ ​ ​ 7,328,549 ​ ​ ​ ​ ​ (i) The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying unaudited interim consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures .

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 31, 2023
Stock-Based Compensation
Stock-Based Compensation	10. Stock-Based Compensation 2011 Equity Incentive Plan The Company’s 2011 Equity Compensation Plan (the “2011 Plan”) provided for the Company to sell or issue restricted common stock, RSUs, performance-based awards (“PSUs”), cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. As of December 31, 2023, PSUs representing 2,470 shares of the Company’s common stock were outstanding under the 2011 Plan. Effective with the December 2015 adoption of the 2015 Equity Incentive Plan, (the “2015 Plan”), no future awards under the 2011 Plan will be granted. 2015 Equity Incentive Plan In December 2015, the Company adopted the 2015 Plan. The 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. The aggregate number of shares of common stock authorized for issuance pursuant to the Company’s 2015 Plan is 42,265,841. As of December 31, 2023, 15,389,080 shares remained available for grant under the 2015 Plan. Stock options and RSUs are granted under the Company’s 2015 Plan and generally vest over a period of one The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations for the three months ended December 31, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Research and development ​ $ 231,416 ​ $ 290,656 General and administrative ​ ​ 1,041,195 ​ ​ 1,101,737 ​ ​ $ 1,272,611 ​ $ 1,392,393 ​ Stock options As of December 31, 2023 options to purchase common stock of the Company outstanding under the 2015 Plan were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 23,956,279 ​ $ 1.44 ​ ​ ​ ​ ​ Granted ​ 2,559,158 ​ ​ 0.29 ​ ​ ​ ​ ​ Forfeited or expired ​ (533,328) ​ ​ 1.37 ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 25,982,109 ​ $ 1.32 ​ 7.5 ​ $ 307,927 Exercisable at December 31, 2023 ​ 16,097,527 ​ $ 1.42 ​ 7.0 ​ $ 76,981 Vested and expected to vest at December 31, 2023 ​ 25,982,109 ​ $ 1.32 ​ 7.5 ​ $ 307,927 ​ The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. The weighted average grant date fair value of the options awarded to employees for the three months ended December 31, 2023 and 2022 was $0.26 and $0.99 per option, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ 2023 2022 ​ Risk-free interest rate 4.6 % 3.9 % Expected term (years) ​ 5.5 ​ 5.3 ​ Expected volatility ​ 130.6 % 115.0 % Expected dividend yield ​ — ​ — ​ ​ As of December 31, 2023, there was $7,989,001 of unrecognized compensation expense that is expected to be recognized over a weighted-average period of 1.9 years. ​ Performance-based stock options ​ The Company granted certain officers of the Company option awards whose vesting is contingent upon meeting company-wide performance goals. The performance stock options were granted “at-the-money” and have a term of 10 years. ​ The fair value of each option grant under the performance share option plan was estimated on the date of grant using the same option valuation model used for non-statutory options above. Compensation expense for performance-based stock options is only recognized when management determines it is probable that the awards will vest. ​ A summary of the activity under the performance share option plan as of December 31, 2023 and changes during the three months then ended are presented below. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 700,000 ​ $ 1.44 ​ ​ ​ ​ ​ Granted ​ — ​ ​ 1.44 ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ — Exercisable at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ — Vested and expected to vest at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ — ​ The weighted average grant date fair value of the performance stock options awarded during the three months ended December 31, 2022, was $0.91 per option. As of December 31, 2023, the Company assessed that the performance conditions related to the performance options granted were not probable of achievement. The assessment was based on the relevant facts and circumstances and therefore no compensation costs were recognized. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ ​ 2022 ​ Risk-free interest rate ​ ​ ​ 3.8 % Expected term (years) ​ ​ ​ 10.0 ​ Expected volatility ​ ​ ​ 91.3 % Expected dividend yield ​ ​ ​ — ​ ​ Performance-based stock units The Company has issued PSUs, which generally have a ten-year term from the date of grant. Upon exercise, the PSU holder receives common stock or cash at the Company’s discretion. The following table summarizes the activity related to PSUs during the three months ended December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ Number ​ Base ​ Remaining ​ ​ ​ ​ ​ of ​ Price ​ Contractual ​ Aggregate ​ PSUs Per PSU Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 2,470 ​ $ 49.97 ​ ​ ​ ​ ​ Forfeitures ​ — ​ ​ — ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — Exercisable at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — Vested and expected to vest at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — ​

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Dec. 31, 2023
Related-Party Transactions
Related-Party Transactions	11. Related-Party Transactions MTTR - strategic partnership agreement (ONS-5010) In February 2018, the Company entered into a strategic partnership agreement with MTTR to advise on regulatory, clinical and commercial strategy and assist in obtaining approval of ONS-5010. In November 2018, the board of directors of the Company appointed Mr. Terry Dagnon as Chief Operations Officer and Mr. Jeff Evanson as Chief Commercial Officer. Both Mr. Dagnon and Mr. Evanson initially provided services to the Company pursuant to the February 2018 strategic partnership agreement with MTTR, as amended. Mr. Dagnon and Mr. Evanson were both principals in MTTR. Both Mr. Dagnon and Mr. Evanson were compensated directly by MTTR for services provided to the Company as the Company's Chief Operations Officer and Chief Commercial Officer, respectively, pursuant to the strategic partnership agreement until such agreement, as amended, was terminated effective March 19, 2020. The Company began compensating Mr. Dagnon and Mr. Evanson directly as consultants effective March 19, 2020 pursuant to their respective consulting agreements with the Company, which became effective March 19, 2020 following stockholder approval of the share issuances contemplated therein. ​ On January 27, 2020, the Company entered into a termination agreement and mutual release with MTTR to terminate the strategic partnership agreement. Pursuant to the agreement, the Company agreed (x) to issue to the four principals of MTTR (who include two of its named executive officers, Messrs. Dagnon and Evanson) an aggregate of 7,244,739 shares of its common stock, subject to stockholder approval, (y) to enter into consulting agreements with each of the four principals setting forth the terms of his respective compensation arrangement, and (z) to pay MTTR a one-time settlement fee of $110,000 upon effectiveness of the agreement. The restricted stock compensation expense was accelerated during the year ended September 30, 2022 as a result of the Company achieving certain performance conditions related to the Company’s BLA submission and the corresponding repurchase rights lapsing. ​ Concurrently, the Company also entered into consulting agreements directly with each of the four principals of MTTR setting forth the terms of his respective compensation arrangement, as well as providing for certain transfer restrictions and repurchase rights applicable to the shares of common stock to be issued pursuant hereto. The termination agreement and the consulting agreements became effective upon stockholder approval of the share issuance on March 19, 2020. ​ On December 21, 2021, the Company entered into employment agreements with each of Mr. Dagnon and Mr. Evanson, which superseded and replaced their prior consulting agreements. Pursuant to their new employment agreements, each of Mr. Dagnon and Mr. Evanson will receive a base salary of $450,000 and a discretionary annual cash bonus with a target amount equal to 50% of his respective base salary. In connection with their entry into the employment agreements, each of Mr. Dagnon and Mr. Evanson received a grant of 800,000 options to purchase common stock, one quarter of which will vest on the first anniversary of the grant and the remainder of which will vest in monthly installments over the succeeding three years , subject to their continued service through each vesting date. In addition, each of Mr. Dagnon and Mr. Evanson received a performance grant of 200,000 options to purchase common stock, which will vest upon the Company’s achievement of certain milestones. An aggregate of 200,000 performance-based stock options vested as a result of achieving the performance condition related to the Company’s BLA submission. Mr. Dagnon transitioned from Chief Operations Officer to Senior Advisor on December 6, 2023, as part of the Company's strategic organizational realignment program. During the three months ended December 31, 2023 and 2022, MTTR and its four principals under the strategic partnership agreement and the subsequent individual consulting agreements earned an aggregate of $60,000 and $58,069 , respectively, which includes monthly consulting fees and expense reimbursement. There were no amounts payable to the former MTTR principals at December 31, 2023 and September 30, 2023.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2023
Subsequent Events
Subsequent Events	12. Subsequent Events Private Placement Securities Purchase Agreement On January 22, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the institutional and accredited investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, and the Investors agreed to purchase, in the Private Placement an aggregate of $60,000,000 in shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, and, for each Share issued in the Private Placement, accompanying warrants to purchase up to one and a half shares of common stock (the “Warrants” and, together with the Shares, the “Securities”). The purchase price per Share and accompanying Warrant will be equal to the lower of (a) $0.35 and (b) the Market Price of the common stock as of the Closing (as defined below) (the “Per Share Price”). “Market Price” means the lower of (i) the closing price of the common stock on the Nasdaq Capital Market as of the trading day immediately preceding Closing (the “Pricing Date”) and (ii) the volume weighted average price (“VWAP”) of the common stock on the Nasdaq Capital Market over the five trading days prior to the Closing (but in no event lower than $0.07 per share). The Warrants will have a per share exercise price equal to 110% of the Per Share Price, subject to proportional adjustments in the event of stock splits or combinations or similar events (such as the reverse stock split to be implemented prior to Closing as discussed below). The Warrants will be exercisable only for cash, except in limited circumstances, at any time after the date of issuance (the “Issue Date”) and will expire five years from the Issue Date. A holder of Warrants may not exercise the Warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock ( 4.99% , 9.99% or 19.99% , as applicable), immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”), which may be increased or decreased at the holders’ option (not to exceed 19.99% ), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the Warrants under certain circumstances as follows: (i) if the VWAP of the common stock equals or exceeds $1.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split to be implemented prior to Closing as discussed below) for 30 consecutive days (the “Stock Price Condition”) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial’s primary endpoints (the “NORSE EIGHT Announcement”), upon the consent of a majority of the members of the Company’s Board of Directors (the “Board”), the Company may require the holders to exercise up to 20% of the aggregate number of Warrants issued to such holder on the Issue Date; and (ii) the Company may require up to the remainder of the Warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010, upon the consent of a majority of the members of the Board or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company’s Board of Directors present at duly called meeting. The closing of the Private Placement (the “Closing”) is conditioned on (i) the filing of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock by at least a number of shares sufficient to issue the Shares and the shares of common stock issuable upon exercise of the Warrants (the “Warrant Shares”), (ii) the implementation of a reverse stock split of the common stock, and (iii) stockholder approval of the issuance of the Securities in the Private Placement. The Company intends to seek to obtain approval of each of the foregoing at its 2024 annual meeting of stockholders (collectively, the “Stockholder Approval”). The Private Placement will not close, the Securities will not be issued, and the proceeds of the Private Placement will not be received by the Company unless and until the Stockholder Approval is obtained and the reverse stock split is implemented. The Company anticipates receiving gross proceeds of $60,000,000 at the Closing and may receive up to an additional $99,000,000 of gross proceeds upon cash exercise of the Warrants, in each case before deducting placement agent fees and offering expenses. Bank of America Securities and BTIG acted as co-placement agents in connection with the financing. The Securities Purchase Agreement may be terminated if the Stockholder Approval is not obtained by April 15, 2024 or if Closing has not occurred prior to the 15th trading day following receipt of Stockholder Approval. Syntone Private Placement Purchase Agreement In addition, on January 22, 2024, the Company entered into a securities purchase agreement (the “Syntone Purchase Agreement”) with Syntone, pursuant to which Syntone agreed to purchase $5,000,000 of shares of common stock (the “Syntone Shares”) and, for each Syntone Share issued under the Syntone Purchase Agreement, accompanying warrants to purchase up to one December 2022 Note Amendment On January 22, 2024, the Company entered into the Note Amendment with the December 2022 Lender. Pursuant to the Note Amendment, the Lender agreed, subject to the satisfaction of certain conditions, to the following conditional amendments (collectively, the “Conditional Amendments”): (i) a reduction in the initial conversion price with respect to $15,000,000 in aggregate principal amount of the Note to the price per share in an issuance of equity securities by the Company resulting in aggregate gross proceeds of at least $25,000,000 (a “Qualified Offering”) (which the Company expects to result in a reduction of the initial conversion price such that it equals the Per Share Price in the Private Placement) (the “Conversion Price Adjustment”), which would apply to conversions on or after April 1, 2024; (ii) an extension of the maturity date of the Note to July 1, 2025; (iii) an extension fee of 7.5% of the outstanding balance of the Note, which amount will be calculated and added to the outstanding balance on the date a Qualified Offering is completed; (iv) an increase of the rate at which interest will accrue on the Note from 9.5% to the prime rate (as published in the Wall Street Journal) plus 3% (subject to a floor of 9.5%); and (v) an obligation of the Company to repay at least $3,000,000 of the outstanding balance of the Note for each calendar quarter beginning with the second quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the December 2022 Note and continuing until it is repaid in full.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Basis of presentation	Basis of presentation The accompanying unaudited interim consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of December 31, 2023 and its results of operations for the three months ended December 31, 2023 and 2022, cash flows for the three months ended December 31, 2023 and 2022, and stockholders’ (deficit) equity for the three months ended December 31, 2023 and 2022. Operating results for the three months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending September 30, 2023. The unaudited interim consolidated financial statements presented herein do not contain all of the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended September 30, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on December 22, 2023.
Use of estimates	Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, such as the current macroeconomic environment, including as a result of inflation, high interest rates or ongoing overseas conflict, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.
Net loss per share	Net loss per share Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Potentially dilutive securities include warrants, performance-based stock options and units, stock options and non-vested restricted stock unit (“RSU”) awards using the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company’s loss. The following table sets forth the computation of basic loss per share and diluted loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Net loss attributable to common stockholders ​ $ (11,178,239) ​ $ (18,662,513) Common stock shares outstanding (weighted average) ​ ​ 260,257,517 ​ ​ 227,410,533 Basic and diluted net loss per share ​ $ (0.04) ​ $ (0.08) ​ The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding as of December 31, 2023 and 2022, as they would be antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ 2023 2022 ​ Performance-based stock units ​ 2,470 ​ 2,470 ​ Performance-based stock options ​ 700,000 ​ 1,900,000 ​ Stock options ​ 25,982,109 ​ 20,726,330 ​ Common stock warrants ​ 7,328,549 ​ 7,328,549 ​ Convertible debt ​ 17,519,402 ​ 15,910,000 (i) ​ (i) The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of $2.00 per share, which is subject to change as described in Note 7. ​
Recently issued accounting pronouncements	Recently issued accounting pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Schedule of computation of basic earnings per share and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Net loss attributable to common stockholders ​ $ (11,178,239) ​ $ (18,662,513) Common stock shares outstanding (weighted average) ​ ​ 260,257,517 ​ ​ 227,410,533 Basic and diluted net loss per share ​ $ (0.04) ​ $ (0.08)
Schedule of dilutive securities excluded from the computation weighted-average shares	​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ 2023 2022 ​ Performance-based stock units ​ 2,470 ​ 2,470 ​ Performance-based stock options ​ 700,000 ​ 1,900,000 ​ Stock options ​ 25,982,109 ​ 20,726,330 ​ Common stock warrants ​ 7,328,549 ​ 7,328,549 ​ Convertible debt ​ 17,519,402 ​ 15,910,000 (i) ​ (i) The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of $2.00 per share, which is subject to change as described in Note 7. ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 31, 2023
Fair value
Schedule of assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured convertible promissory note ​ $ — ​ $ — ​ $ 36,544,000 Warrant liability ​ ​ — ​ ​ — ​ ​ 59,561 Total ​ $ — ​ $ — ​ $ 36,603,561 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ (Level 1) (Level 2) (Level 3) Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured convertible promissory note ​ $ — ​ $ — ​ $ 35,551,000 Warrant liability ​ ​ — ​ ​ — ​ ​ 6,219 Total ​ $ — ​ $ — ​ $ 35,557,219
Schedule of changes in the fair value of Level 3 liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured Convertible ​ ​ ​ ​ Promissory Note Warrants Balance at October 1, 2023 ​ $ 35,551,000 ​ $ 6,219 Change in fair value ​ ​ 993,000 ​ ​ 53,342 Balance at December 31, 2023 ​ $ 36,544,000 ​ $ 59,561 ​
December 2022 Note
Fair value
Schedule of fair value inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 ​ Term (years) ​ ​ 0.3 ​ ​ 0.3 ​ Stock price ​ $ 0.39 ​ $ 0.22 ​ Volatility ​ ​ 186.0 % ​ 71.0 % Risk-free rate ​ ​ 5.4 % ​ 5.5 % Dividend yield ​ ​ — % ​ — % Credit-adjusted discount rate ​ ​ 21.8 % ​ 22.8 %
Warrant liability
Fair value
Schedule of fair value inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 ​ Risk-free interest rate ​ ​ 4.72 % ​ 5.30 % Remaining contractual term of warrants (years) ​ ​ 1.1 ​ ​ 1.4 ​ Expected volatility ​ ​ 235.4 % ​ 158.3 % Annual dividend yield ​ ​ — % ​ — % Fair value of common stock (per share) ​ $ 0.39 ​ $ 0.22 ​ ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Dec. 31, 2023
Accrued Expenses
Schedule of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ September 30, 2023 Compensation ​ $ 1,112,512 ​ $ 919,970 Research and development ​ ​ 1,631,674 ​ ​ 1,234,192 Professional fees ​ ​ 1,161,512 ​ ​ 165,192 Other accrued expenses ​ ​ 181,072 ​ ​ 426,386 ​ ​ $ 4,086,770 ​ $ 2,745,740 ​

Debt (Tables)

Debt (Tables)	3 Months Ended
	Dec. 31, 2023
Debt
Schedule of debt	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 September 30, 2023 Unsecured convertible promissory note (measured at fair value) ​ $ 36,544,000 ​ $ 35,551,000 Less: current portion ​ ​ (36,544,000) ​ ​ (35,551,000) Long-term debt ​ $ — ​ $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Dec. 31, 2023
Commitments and Contingencies
Schedule of lease information	The components of lease cost for the three months ended December 31, 2023 and 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Lease cost: ​ ​ Amortization of right-of-use assets ​ $ — ​ $ — Interest on lease liabilities ​ 104 ​ 491 Total finance lease cost ​ 104 ​ 491 Operating lease cost ​ 11,217 ​ 11,217 Total lease cost ​ $ 11,321 ​ $ 11,708 ​ Amounts reported in the unaudited interim consolidated balance sheets for leases where the Company is the lessee are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 September 30, 2023 Operating leases: ​ ​ ​ Right-of-use asset ​ $ 14,956 ​ $ 26,172 Operating lease liabilities ​ — ​ — Finance leases: ​ ​ Right-of-use asset ​ $ — ​ $ — Financing lease liabilities ​ 1,084 ​ 4,267 Weighted-average remaining lease term (years): ​ ​ Operating leases ​ ​ 0.3 ​ ​ 0.6 Finance leases ​ — ​ 0.3 Weighted-average discount rate: ​ ​ Operating leases ​ ​ 7.5% ​ ​ 7.5% Finance leases ​ 13.0% ​ 13.0% ​ Other information related to leases for the three months ended December 31, 2023 and 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Cash paid for amounts included in the measurement of lease obligations: ​ ​ ​ Operating cash flows from finance leases ​ $ 104 ​ $ 491 Operating cash flows from operating leases ​ — ​ 11,861 Financing cash flows from finance leases ​ 3,183 ​ 2,797
Schedule of finance lease future minimum payments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance leases 2024 (remaining one month) ​ ​ ​ ​ $ 1,096 Less: Imputed interest ​ ​ ​ ​ 12 Total lease obligations ​ ​ ​ ​ $ 1,084 ​

Common Stock and Stockholders_2

Common Stock and Stockholders' Equity (Tables)	3 Months Ended
	Dec. 31, 2023
Common Stock and Stockholders' Equity
Schedule of warrants outstanding	As of December 31, 2023, shares of common stock issuable upon the exercise of outstanding warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares of ​ ​ ​ ​ ​ common stock ​ ​ ​ ​ ​ issuable upon ​ ​ ​ ​ ​ exercise of ​ Exercise Price ​ Expiration Date warrants Per Share ​ December 22, 2024 (i) 277,128 ​ $ 12.00 ​ February 26, 2024 ​ 1,747,047 ​ $ 0.9535 ​ February 24, 2025 ​ 172,864 ​ $ 1.27 ​ April 13, 2025 (i) 145,686 ​ $ 12.00 ​ May 31, 2025 (i) 62,437 ​ $ 12.00 ​ June 22, 2025 ​ 191,268 ​ $ 1.51875 ​ December 28, 2025 ​ 515,755 ​ $ 1.0500 ​ January 28, 2026 ​ 2,116,364 ​ $ 1.25 ​ November 23, 2026 ​ 2,100,000 ​ $ 1.5625 ​ ​ ​ 7,328,549 ​ ​ ​ ​ ​ (i) The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying unaudited interim consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures .

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2023
Share-based Compensation
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ 2023 2022 Research and development ​ $ 231,416 ​ $ 290,656 General and administrative ​ ​ 1,041,195 ​ ​ 1,101,737 ​ ​ $ 1,272,611 ​ $ 1,392,393
Schedule of performance-based stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ Number ​ Base ​ Remaining ​ ​ ​ ​ ​ of ​ Price ​ Contractual ​ Aggregate ​ PSUs Per PSU Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 2,470 ​ $ 49.97 ​ ​ ​ ​ ​ Forfeitures ​ — ​ ​ — ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — Exercisable at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — Vested and expected to vest at December 31, 2023 ​ 2,470 ​ $ 49.97 ​ 0.5 ​ $ — ​
Employee Stock Option [Member]
Share-based Compensation
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 23,956,279 ​ $ 1.44 ​ ​ ​ ​ ​ Granted ​ 2,559,158 ​ ​ 0.29 ​ ​ ​ ​ ​ Forfeited or expired ​ (533,328) ​ ​ 1.37 ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 25,982,109 ​ $ 1.32 ​ 7.5 ​ $ 307,927 Exercisable at December 31, 2023 ​ 16,097,527 ​ $ 1.42 ​ 7.0 ​ $ 76,981 Vested and expected to vest at December 31, 2023 ​ 25,982,109 ​ $ 1.32 ​ 7.5 ​ $ 307,927
Schedule of option assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ 2023 2022 ​ Risk-free interest rate 4.6 % 3.9 % Expected term (years) ​ 5.5 ​ 5.3 ​ Expected volatility ​ 130.6 % 115.0 % Expected dividend yield ​ — ​ — ​
Performance-based stock options
Share-based Compensation
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ ​ ​ ​ Weighted ​ Remaining ​ ​ ​ ​ ​ Number of ​ Average ​ Contractual ​ Aggregate ​ Shares Exercise Price Term (Years) Intrinsic Value Balance at October 1, 2023 ​ 700,000 ​ $ 1.44 ​ ​ ​ ​ ​ Granted ​ — ​ ​ 1.44 ​ ​ ​ ​ ​ Balance at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ — Exercisable at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ — Vested and expected to vest at December 31, 2023 ​ 700,000 ​ $ 1.44 ​ 8.0 ​ $ —
Schedule of option assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended December 31, ​ ​ ​ ​ 2022 ​ Risk-free interest rate ​ ​ ​ 3.8 % Expected term (years) ​ ​ ​ 10.0 ​ Expected volatility ​ ​ ​ 91.3 % Expected dividend yield ​ ​ ​ — ​

Liquidity (Details)

Liquidity (Details) - USD ($)		1 Months Ended
	Jan. 22, 2024	Jan. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	May 16, 2023
Accumulated deficit			$ 479,096,425	$ 467,918,186
Debt, interest, fees			$ 37,666,716
Subsequent Events | Investor
Aggregate maximum offering price	$ 60,000,000	$ 60,000,000
Expected maximum proceeds	99,000,000	99,000,000
Subsequent Events | Syntone Ventures, LLC
Aggregate maximum offering price	$ 5,000,000	$ 5,000,000
BTIG ATM
Aggregate maximum offering price					$ 100,000,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - EPS (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Basic and diluted earnings per share:
Net loss attributable to common stockholders	$ (11,178,239)	$ (18,662,513)
Basic Earnings Per Share
Common stock shares outstanding (weighted average), basic (in shares)	260,257,517	227,410,533
Basic net loss per share (in dollars per share)	$ (0.04)	$ (0.08)
Diluted Earnings Per Share
Common stock shares outstanding (weighted average), diluted (in shares)	260,257,517	227,410,533
Diluted net loss per share (in dollars per share)	$ (0.04)	$ (0.08)

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Dilutive (Details) - $ / shares	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Performance-based stock units
Antidilutive securities
Antidilutive securities excluded from computation of earnings per share	2,470	2,470
Performance-based stock options
Antidilutive securities
Antidilutive securities excluded from computation of earnings per share	700,000	1,900,000
Employee Stock Option [Member]
Antidilutive securities
Antidilutive securities excluded from computation of earnings per share	25,982,109	20,726,330
Common stock warrants
Antidilutive securities
Antidilutive securities excluded from computation of earnings per share	7,328,549	7,328,549
Convertible debt
Antidilutive securities
Antidilutive securities excluded from computation of earnings per share	17,519,402	15,910,000
Conversion rate per share	$ 2

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Liabilities
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Warrants and Rights Outstanding	Warrants and Rights Outstanding
Fair value measurements recurring basis | Level 3
Liabilities
Unsecured convertible promissory note	$ 36,544,000	$ 35,551,000
Warrant liability	59,561	6,219
Total	$ 36,603,561	$ 35,557,219

Fair Value Measurements - Chang

Fair Value Measurements - Changes in fair value (Details)	3 Months Ended
	Dec. 31, 2023 USD ($)
December 2022 Note
Liabilities fair value changes
Balance, beginning	$ 35,551,000
Change in fair value	$ 993,000
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Change In Fair Value Of Redemption Feature
Balance, ending	$ 36,544,000
Warrant liability
Liabilities fair value changes
Balance, beginning	6,219
Change in fair value	$ 53,342
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment of Warrants
Balance, ending	$ 59,561

Fair Value Measurements - Assum

Fair Value Measurements - Assumptions (Details)	Dec. 31, 2023 $ / shares Y	Sep. 30, 2023 $ / shares Y
Expected Term
Fair value inputs
Debt inputs | Y	0.3	0.3
Warrant inputs | Y	1.1	1.4
Stock price (per share)
Fair value inputs
Debt inputs | $ / shares	0.39	0.22
Warrant inputs | $ / shares	0.39	0.22
Expected volatility
Fair value inputs
Debt inputs	1.860	0.710
Warrant inputs	2.354	1.583
Risk-free interest rate
Fair value inputs
Debt inputs	0.054	0.055
Warrant inputs	0.0472	0.0530
Annual dividend yield
Fair value inputs
Debt inputs	0	0
Warrant inputs	0	0
Discount rate
Fair value inputs
Debt inputs	0.218	0.228

Equity Method Investment - Synt

Equity Method Investment - Syntone (Details) - Syntone - USD ($)		1 Months Ended
	May 22, 2020	Jun. 30, 2020
Investments
Ownership percentage	20%
Investment in joint venture		$ 900,000
Expected future investment	$ 2,100,000
Syntone PRC
Investments
Ownership percentage	80%

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Accrued Expenses
Compensation	$ 1,112,512		$ 919,970
Research and development	1,631,674		1,234,192
Professional fees	1,161,512		165,192
Other accrued expenses	181,072		426,386
Accrued expenses, total	$ 4,086,770	$ 2,745,740	$ 2,745,740

Debt - Summary (Details)

Debt - Summary (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Debt
Less: current portion	$ (36,544,000)	$ (35,551,000)
December 2022 Note
Debt
Total debt	$ 36,544,000	$ 35,551,000

Debt - Information (Details)

Debt - Information (Details)			1 Months Ended	3 Months Ended
	Dec. 22, 2022 USD ($) D $ / shares	Nov. 16, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt
Proceeds from loan				$ 30,000,000
Payment of lender fees				568,930
Interest paid				1,158,609
Gain (loss) on extinguishment of debt				(577,659)
December 2022 Note
Debt
Original principal amount	$ 31,820,000
Debt issuance costs	1,820,000		$ 475,000
Proceeds from loan	$ 18,052,461
Interest rate (as a percent)	9.50%
Trading day threshold | D	30
Percentage of additional fee on payments in cash	7.50%
Percentage of increase in debt balance by lender for a Major Trigger Event	10%
Percentage of increase in debt balance by lender for a Minor Trigger Event	5%
Threshold trading days of written notice from Lender for cure of Trigger Event	10 days
Interest rate for the immediately due and payable amounts	22%
Conversion rate per share | $ / shares	$ 2.50
Conversion price required to satisfy conversion notice from the lender in cash | $ / shares	$ 0.1756
Percentage of participation right to Lender in future debt or equity financing	10%
Interest expense				2,074,964
Payment of lender fees				254,964
December 2022 Note | Major Trigger Event
Debt
Trading day threshold | D	3
Conversion rate per share | $ / shares	$ 2
Threshold percentage of stock price trigger	90%
November 2021 Note
Debt
Original principal amount		$ 10,220,000
Proceeds from loan		$ 10,000,000
Interest rate (as a percent)		9.50%
Interest expense				454,866
Unamortized discount		$ 820,000
Redemption price (as a percent)	105%	105%
Repayments of unsecured debt	$ 11,947,539
Interest paid	1,158,609
Gain (loss) on extinguishment of debt	(577,659)
Amortization of debt issuance costs	8,729			$ 190,775
Prepayment fee	$ 568,930

Commitments and Contingencies -

Commitments and Contingencies - Lease cost (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2021
Leases
Finance lease term			3 years
Lease cost
Interest on lease liabilities	$ 104	$ 491
Total finance lease cost	104	491
Operating lease cost	11,217	11,217
Total lease cost	$ 11,321	$ 11,708
Minimum
Leases
Finance lease term	12 months
Finance lease interest (as a percent)	4%
Maximum
Leases
Finance lease term	36 months
Finance lease interest (as a percent)	13%

Commitments and Contingencies_2

Commitments and Contingencies - Lease balance sheet (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Leases
Operating leases, Right-of-use asset	$ 14,956	$ 26,172
Financing lease liabilities	$ 1,084	$ 4,267
Operating leases, Weighted-average remaining lease term	3 months 18 days	7 months 6 days
Finance leases, Weighted-average remaining lease term		3 months 18 days
Operating leases, Weighted-average discount rate (as a percent)	7.50%	7.50%
Finance leases, Weighted-average discount rate (as a percent)	13%	13%

Commitments and Contingencies_3

Commitments and Contingencies - Lease cash flow (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating cash flows from finance leases	$ 104	$ 491
Operating cash flows from operating leases		11,861
Financing cash flows from finance leases	$ 3,183	$ 2,797

Commitments and Contingencies_4

Commitments and Contingencies - Lease minimum payments (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Finance leases
2024 (remaining one month)	$ 1,096
Less: Imputed interest	12
Total lease obligations	$ 1,084	$ 4,267

Common Stock and Stockholders_3

Common Stock and Stockholders' Equity - Common Stock (Details) - USD ($)			1 Months Ended	3 Months Ended
	May 16, 2023	Mar. 26, 2021	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023	Mar. 29, 2023	Mar. 28, 2023
Common Stock and Stockholders' Equity
Common stock, shares authorized				425,000,000		425,000,000	425,000,000	325,000,000
Proceeds from issuance of stock					$ 24,637,009
Shares of common stock issuable upon exercise of warrants				7,328,549
Direct registered offering
Common Stock and Stockholders' Equity
Shares issued price (in dollars per share)			$ 0.8784		$ 0.8784
Proceeds from issuance of stock			$ 23,208,679
Sale of common stock, net of issuance costs (in shares)			28,460,831
Direct registered offering | GMS Ventures & Investments
Common Stock and Stockholders' Equity
Sale of common stock, net of issuance costs (in shares)			14,230,418
Direct registered offering | M.S. Howells & Co
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants			515,755		515,755
Exercise price per share			$ 1.05		$ 1.05
Warrants exercise term			3 years		3 years
Wainwright ATM offering
Common Stock and Stockholders' Equity
Proceeds from issuance of stock					$ 1,089,105
Aggregate maximum offering price		$ 40,000,000
Amount reclassified on additional paid in capital		$ 197,654
Payment of fees to sales agent					$ 38,799
Percentage of commission on sale of common stock		3%
Sale of common stock, net of issuance costs (in shares)					895,391
BTIG ATM
Common Stock and Stockholders' Equity
Aggregate maximum offering price	$ 100,000,000
Amount reclassified on additional paid in capital	$ 353,688
Deferred costs				$ 331,512
Percentage of commission on sale of common stock				3%
Sale of common stock, net of issuance costs (in shares)				0

Common Stock and Stockholders_4

Common Stock and Stockholders' Equity - Warrants (Details)	Dec. 31, 2023 $ / shares shares
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	7,328,549
December 22, 2024
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	277,128
Exercise price per share | $ / shares	$ 12
February 26, 2024
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	1,747,047
Exercise price per share | $ / shares	$ 0.9535
February 24, 2025
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	172,864
Exercise price per share | $ / shares	$ 1.27
April 13, 2025
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	145,686
Exercise price per share | $ / shares	$ 12
May 31, 2025
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	62,437
Exercise price per share | $ / shares	$ 12
June 22, 2025
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	191,268
Exercise price per share | $ / shares	$ 1.51875
December 28, 2025
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	515,755
Exercise price per share | $ / shares	$ 1.0500
January 28, 2026
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	2,116,364
Exercise price per share | $ / shares	$ 1.25
November 23, 2026
Common Stock and Stockholders' Equity
Shares of common stock issuable upon exercise of warrants	2,100,000
Exercise price per share | $ / shares	$ 1.5625

Stock-Based Compensation - Info

Stock-Based Compensation - Information (Details)	3 Months Ended
	Dec. 31, 2023 shares
Performance-based stock units
Share-based Compensation
Term of award	10 years
2011 Equity Incentive Plan | Performance-based stock units
Share-based Compensation
Awards outstanding	2,470
2015 Equity Incentive Plan
Share-based Compensation
Aggregate number of common stock authorized for issuance	42,265,841
Number of shares available for grant	15,389,080
Term of award	10 years
2015 Equity Incentive Plan | Minimum
Share-based Compensation
Vesting period	1 year
2015 Equity Incentive Plan | Maximum
Share-based Compensation
Vesting period	4 years

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation
Stock-based compensation expense	$ 1,272,611	$ 1,392,393
Research and development
Share-based Compensation
Stock-based compensation expense	231,416	290,656
General and administrative
Share-based Compensation
Stock-based compensation expense	$ 1,041,195	$ 1,101,737

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock option activity (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Weighted Average Remaining Contractual Term (Years)
Stock-based compensation expense	$ 1,272,611	$ 1,392,393
Employee Stock Option [Member]
Number of Shares
Balance, Beginning (in shares)	23,956,279
Granted (in shares)	2,559,158
Forfeited or expired (in shares)	(533,328)
Balance, Ending (in shares)	25,982,109
Vested and exercisable (in shares)	16,097,527
Vested and expected to vest (in shares)	25,982,109
Weighted Average Exercise Price
Balance, Beginning (in dollars per share)	$ 1.44
Granted (in dollars per share)	0.29
Forfeited or expired (in dollars per share)	1.37
Balance, Ending (in dollars per share)	1.32
Vested and exercisable (in dollars per share)	1.42
Vested and expected to vest (in dollars per share)	$ 1.32
Weighted Average Remaining Contractual Term (Years)
Balance-Remaining contractual term	7 years 6 months
Vested and exercisable -Remaining contractual term	7 years
Vested and expected to vest-Remaining contractual term	7 years 6 months
Aggregate intrinsic value, Outstanding	$ 307,927
Aggregate intrinsic value, Vested and exercisable	76,981
Aggregate intrinsic value, Vested and expected to vest	$ 307,927
Grant date fair value of options (in dollars per share)	$ 0.26	$ 0.99
Performance-based stock options
Number of Shares
Balance, Beginning (in shares)	700,000
Balance, Ending (in shares)	700,000
Vested and exercisable (in shares)	700,000
Vested and expected to vest (in shares)	700,000
Weighted Average Exercise Price
Balance, Beginning (in dollars per share)	$ 1.44
Granted (in dollars per share)	1.44
Balance, Ending (in dollars per share)	1.44
Vested and exercisable (in dollars per share)	1.44
Vested and expected to vest (in dollars per share)	$ 1.44
Weighted Average Remaining Contractual Term (Years)
Balance-Remaining contractual term	8 years
Vested and exercisable -Remaining contractual term	8 years
Vested and expected to vest-Remaining contractual term	8 years
Term of award	10 years
Grant date fair value of options (in dollars per share)		$ 0.91

Stock-Based Compensation - Opti

Stock-Based Compensation - Option Assumptions (Details) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Stock Option [Member]
Share-based Compensation
Risk-free interest rate	4.60%	3.90%
Expected term (years)	5 years 6 months	5 years 3 months 18 days
Expected volatility	130.60%	115%
Expected dividend yield	0%	0%
Unrecognized compensation expense	$ 7,989,001
Unrecognized compensation exercise period	1 year 10 months 24 days
Performance-based stock options
Share-based Compensation
Risk-free interest rate		3.80%
Expected term (years)		10 years
Expected volatility		91.30%
Expected dividend yield		0%

Stock-Based Compensation - Non-

Stock-Based Compensation - Non-options (Details) - Performance-based stock units	3 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-based Compensation
Term of award	10 years
Number of PSUs
Balance, Beginning	2,470
Forfeitures
Balance, Ending	2,470
Vested and exercisable	2,470
Vested and expected to vest	2,470
Weighted Average Base Price Per Unit
Balance, Beginning | $ / shares	$ 49.97
Forfeitures | $ / shares
Balance, Ending | $ / shares	49.97
Vested and exercisable | $ / shares	$ 49.97
Vested and expected to vest	49.97%
Weighted average remaining contractual term, Outstanding	6 months
Weighted average remaining contractual term, Vested and exercisable	6 months
Weighted average remaining contractual term, Vested and expected to vest	6 months

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)			3 Months Ended
	Dec. 21, 2021	Jan. 27, 2020	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023
Related party
Research and development			$ 4,529,358	$ 9,862,424
Accounts payable			$ 3,480,326		$ 6,574,523
Employee Stock Option [Member]
Related party
Number of options granted			2,559,158
Related Party | Employee Stock Option [Member]
Related party
Vesting (as a percent)	25%
Vesting period	3 years
Related Party | Performance-based stock options
Related party
Number of stock options vested			200,000
Related Party | MTTR
Related party
Shares issued during period		7,244,739
Contract termination settlement fee		$ 110,000
Research and development			$ 60,000	$ 58,069
Accounts payable			$ 0		$ 0
Related Party | Terry Dagnon
Related party
Base salary	$ 450,000
Percentage of cash bonus	50%
Related Party | Terry Dagnon | Employee Stock Option [Member]
Related party
Number of options granted	800,000
Related Party | Terry Dagnon | Performance-based stock options
Related party
Number of options granted	200,000
Related Party | Jeff Evanson
Related party
Base salary	$ 450,000
Percentage of cash bonus	50%
Related Party | Jeff Evanson | Employee Stock Option [Member]
Related party
Number of options granted	800,000
Related Party | Jeff Evanson | Performance-based stock options
Related party
Number of options granted	200,000

Subsequent Events - Securities

Subsequent Events - Securities (Details) - USD ($)		1 Months Ended	3 Months Ended
	Jan. 22, 2024	Jan. 31, 2024	Dec. 31, 2022	Dec. 31, 2023	Sep. 30, 2023
Subsequent Events
Common stock, par value				$ 0.01	$ 0.01
Proceeds from issuance of stock			$ 24,637,009
Subsequent Events | Investor
Subsequent Events
Aggregate maximum offering price	$ 60,000,000	$ 60,000,000
Common stock, par value	$ 0.01
Warrants to purchase on each share of common stock	1.5
Warrants exercise term	5 years
Beneficial ownership exercise restriction, one (as a percent)	4.99%
Beneficial ownership exercise restriction, two (as a percent)	9.99%
Beneficial ownership exercise restriction, three (as a percent)	19.99%
Warrant holders exercise under certain conditions (as a percent)	20%
Expected maximum proceeds	$ 99,000,000	99,000,000
Subsequent Events | Investor | Minimum
Subsequent Events
Exercise price per share	$ 0.07
Subsequent Events | Investor | Maximum
Subsequent Events
Exercise price per share	$ 0.35
Subsequent Events | Syntone Ventures, LLC
Subsequent Events
Aggregate maximum offering price	$ 5,000,000	$ 5,000,000
Warrants to purchase on each share of common stock	1.5

Subsequent Events - Debt Amendm

Subsequent Events - Debt Amendment (Details) - December 2022 Note - USD ($)	Jan. 22, 2024	Dec. 22, 2022
Subsequent Events
Interest rate (as a percent)		9.50%
Subsequent Events
Subsequent Events
Aggregate principal amount on which initial conversion price is reduced	$ 15,000,000
Minimum aggregate gross proceeds from reduction in initial conversion price	$ 25,000,000
Extension fee as percentage of the outstanding balance	7.50%
Quarterly payment	$ 3,000,000
Subsequent Events | Prime rate
Subsequent Events
Interest rate (as a percent)	9.50%
Spread on variable rate	3%
Floor interest rate	9.50%

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (11,178,239)	$ (18,662,513)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false